Document is current
Any future updates will be listed below
-
Authors
Yarnoff, Benjamin
Beuvelet, Matthieu
Soudani, Samira
Neary, Maureen P.
Hodges, Erin N.
Chit, Ayman
Tribaldos, Maribel
Gabriel, Veronica
Musci, Robert
Geurtsen, Jeroen
Krilov, Leonard R.
-
Funding
Funding for this research was provided by:
Sanofi
- License Information
-
More Information
Article History
Received: 2 September 2025
Accepted: 26 January 2026
First Online: 26 February 2026
Declarations
:
: Matthieu Beuvelet, Samira Soudani, Maureen P. Neary, Erin N. Hodges, Ayman Chit, Maribel Tribaldos, Veronica Gabriel, and Jeroen Geurtsen are employees of Sanofi and may hold shares and/or stock options in the company. Benjamin Yarnoff and Robert Musci are salaried employees of Evidera, Inc. and are not allowed to accept remuneration from any clients for their services. Leonard R. Krilov has served on advisory boards for Sanofi, Merck, and Pfizer and has been a clinical trial investigator for each of these sponsors on RSV programs. He did not receive compensation for participation in the development of this manuscript.
: This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.
